2024

Alex's Lemonade Stand Foundation

Neuroblastoma Impact Report

Alex's Lemonade Stand Foundation for Childhood Cancer™

AlexsLemonade.org

Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra "Alex" Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. By the time Alex passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a worldwide fundraising movement and the largest independent childhood cancer charity in the U.S. ALSF is a leader in funding pediatric cancer research projects across the globe and providing programs to families affected by childhood cancer. For more information, visit AlexsLemonade.org.

With Gratitude

Dear Friend,

All of us here at Alex's Lemonade Stand Foundation (ALSF) would like to sincerely thank you for your support of Alex's mission to find new treatments and cures for childhood cancers like neuroblastoma.

Your support is helping researchers to develop preliminary data, publish their findings, and push forward innovative treatment options. Thanks to you, we are closer to a day where no child will have to suffer from neuroblastoma.

We are truly honored to fight childhood cancer by your side. Thank you for being the driving force behind life-saving cures. Please don't hesitate to reach out if you need anything from us here at ALSF.

Until there's a cure,

Liz & Jay Scott
Alex's Parents & Co-Executive Directors
Alex's Lemonade Stand Foundation

ALSF

Thanks to Supporters Like You

ALSF is the largest independent childhood cancer charity in the U.S., focused on funding critical research and supporting childhood cancer families.

More than $300M raised since 2005

Funded over 1,500 medical research grants at nearly 150 institutions

Supported nearly 30,000 families through key programs like Travel For Care

ALSF is the only childhood cancer research organization that has been given the NCI Peer-Reviewed Funder Designation for rigorous selection of research and grants.

ALSF

Meet a **Neuroblastoma Hero**

MARY JUDITH

Mary Judith is the happiest baby girl who's a big fan of playing peek-a-boo, being held, and going puppy-spotting with her mom. She is not a fan of being cold after bath time, and she especially hates getting her blood pressure taken.

When Mary Judith was 6 months old, she had a period of unexplained, inconsolable crying. She couldn't sleep, couldn't tolerate activities, lost her appetite, began vomiting, and experienced tummy pain upon palpation, leading to an emergency ultrasound of her intestines. Reports of abnormal stool then led ER doctors to check Mary Judith's kidneys, which they discovered was swollen and had a huge mass. The next day, an MRI confirmed that the mass was neuroblastoma.

At 8 months old, Mary Judith began chemotherapy. She recently finished her third round of chemotherapy at Memorial Sloan Kettering (MSK). Mary Judith's parents are hopeful that surgery to remove her tumor will be completed without damaging the blood vessels and surrounding nerves. They also hope that the potential kinase inhibitor treatment will be successful so that their daughter doesn't have to endure further chemotherapy or radiation. Ultimately, they hope she will be cancer-free with no relapse.

Despite all that she's been through at such a young age, Mary Judith is her dad, Andrew's hero, because she remains kind and sweet through everything. "She makes everyone smile," Andrew said. "She even waves at nurses while crying and being poked with painful needles. She has a joy and innocence that is a true model of sanctity."

ALSF-Funded Projects in Neuroblastoma

Thanks to you, we have been able to continue funding breakthrough research for more cures. Read through some of our recently funded research projects in neuroblastoma below:

MYCN-induced molecular clock disruption and metabolic rewiring drive neuroblastoma

Lingzhi Li, PhD
Baylor College of Medicine
Young Investigator Grants, Awarded 2024

Vaccine-boosted CAR T cell therapy for high risk neuroblastoma

Timothy Spear, MD/PhD
Children's Hospital of Philadelphia
Young Investigator Grants, Awarded 2024

Capitalizing on functional genomics with targeted protein degradation in neuroblastoma

Ian Delahunty, PhD
St. Jude Children's Research Hospital
Young Investigator Grants, Awarded 2024

Characterizing the Hippo pathway in high-risk neuroblastoma

Soha Sewani
Emory University
POST Program Grants, Awarded 2024

A complete list of ALSF-funded neuroblastoma projects can be found at:
AlexsLemonade.org/childhood-cancer/type/neuroblastoma/grants

ALSF

Research **Spotlight**

Drugging MYCN

Yael Mossé, MD
Children's Hospital of Philadelphia
Crazy 8 Initiative Award

Yael Mossé, MD and her team have been selected to receive funds from Cancer Grand Challenges, a funding initiative co-founded by the National Cancer Institute and Cancer Research UK. Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer. This is in addition to the funding they have received from ALSF. The team aims to develop drugs that break down or 'degrade' five of the most significant oncoproteins in children with high-risk oncogene-driven cancers, including neuroblastoma, medulloblastoma, Ewing sarcoma, fibrolamellar hepatocellular carcinoma, rhabdomyosarcoma, and other cancers that deregulate these essential oncoproteins.

Dr. Mossé and her team have made substantial progress over the last year of funding, both in the development and testing of MYCN-Aurora CTMs (chimeric targeting molecules) in vivo and in their discovery efforts to identify integral MYCN binding partners for potential therapeutic targeting. Their key collaboration with Nurix Therapeutics is highly collaborative. In the third year of funding, Nurix has developed hundreds of candidate CTMs as potential MYCN degraders that are being screened through the team's pipeline. They are now refining the drug-like properties of these CTMs and entering a DEL (DNA-Encoded chemical Library) screen with purified MYCN bound to RNA. They are also making new discoveries about candidate MYCN interacting proteins. Successful completion of this project, as planned, will lead to curative new drugs for children with currently incurable cancers.

> "We are now poised to deliver on the Holy Grail of pediatric cancer and that is to develop a drug that will allow for MYCN to degrade in a cancer cell and directly impact patients with MYCN-driven childhood cancers."
>
> — Dr. Mossé







Thank You

for all you do to help kids with cancer!